# A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs

> **NCT02720523** · PHASE2,PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 197 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Upadacitinib

## Key facts

- **NCT ID:** NCT02720523
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-22
- **Primary completion:** 2017-08-03
- **Final completion:** 2022-06-07
- **Target enrollment:** 197 (ACTUAL)
- **Last updated:** 2023-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02720523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02720523, "A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02720523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*